IGF1 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided.
IGF IA, IGF IB, IGF-I, IGF1A, IGF1_HUMAN, Insulin like growth factor 1, Insulin like growth factor 1 (somatomedin C), Insulin like growth factor IA, Insulin like growth factor IB, Insulin-like growth factor I, MGF, Mechano growth factor, OTTHUMP00000195080, OTTHUMP00000195081, OTTHUMP00000195082, OTTHUMP00000195083, OTTHUMP00000195084, Somatomedia C, Somatomedin-C
IGF1 KO cell line available to order. KO validated by Next Generation Sequencing. Free of charge wild type control provided.
Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.
1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.
Although we aim to provide customers with a homozygous clone, feasibility will be dependent on the biology of the protein. Should only heterozygous edits be achieved, you will be notified of the outcome and be asked to confirm whether the cell line is acceptable. All clones will be accompanied with DNA sequencing data, and the mutation description.
Recommended control: Human wild-type HCT116 cell line (ab288559). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.
We will provide viable cells that proliferate on revival.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
The insulin-like growth factor 1 or IGF1 is a protein hormone that plays an important mechanical role in growth and development. Alternative names for IGF1 include somatomedin C. This protein has a mass of approximately 7.6 kDa and is mainly produced by the liver. IGF1 is expressed in a range of tissues including muscle bone and cartilage reflecting its importance in various physiological processes. Its production is stimulated by growth hormone and it acts in an autocrine and paracrine manner to exert its effects.
IGF1 stimulates growth and proliferation of cells most notably impacting the development of the skeletal system and the regulation of apoptosis. It is not part of a larger protein complex but it interacts closely with IGF1 receptor to execute its functions. By binding to this receptor IGF1 activates intracellular signaling cascades that promote anabolic effects which include increased uptake of glucose and amino acids contributing to muscle and tissue growth.
IGF1 operates within the PI3K-Akt and MAPK signaling pathways which are significant for cell survival and proliferation. Its interaction with proteins like IGF binding protein 3 (IGFBP3) modulates its availability and activity in the bloodstream. These pathways are critical for mediating the effects of growth hormone highlighting the role of IGF1 in systemic growth and metabolism regulation.
Alterations in IGF1 levels associate with growth abnormalities such as Laron syndrome and acromegaly. Laron syndrome results from the body's inability to use IGF1 properly due to receptor defects while acromegaly occurs from excessive IGF1 production often due to pituitary tumors. Furthermore aberrant IGF1 signaling connects to cancer development where it can drive tumor growth and metastasis. Drugs targeting IGF1 and its pathway components continue to be researched for therapeutic potential in these conditions.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
6 bp deletion and 1 bp insertion after Ala48 (edit 1). 1 bp insertion after Val65 (edit 2).
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com